Key Takeaways Bruker received $10M in new NMR instrumentation orders from NYSBC, Delaware, and Northwestern. BRKR's systems, backed by NIH and NSF funding, will be delivered and installed in 2026. The new orders strengthen Bruker's BioSpin segment and lifted shares 6.2% to $36.98. Bruker Corporation (BRKR) recently received new orders for advanced Nuclear Magnetic Resonance (“NMR”) instrumentation from the New York Structural Biology Center (“NYSBC”), the University of Delaware and Northwestern University. ...

Core Insights - The company reported a quarter with high single-digit instrumentation growth, indicating strong performance in its base business [1] - There was a slight softness in the TA segment, but overall results were better than expected across various areas [1] - The company continues to experience momentum similar to Q1, suggesting a consistent growth trajectory [1] Business Performance - The base business is described as going from strength to strength, with ongoing positive momentum [1] - The company acknowledges a repetitive success pattern, indicating a stable operational strategy [1] Instrument Replacement Cycle - Discussion around the instrument replacement cycle is anticipated, suggesting it is a significant factor for future growth [1]